Li Mingyang, Jin Dongxia, Xie Cun, Cui Xiaodong, Cong Hongliang, Hu Yuecheng
Clinical School of Thoracic, Tianjin Medical University, Tianjin, China.
Department of Cardiology, Chest Hospital of Tianjin University, 261 Tai'erzhuang Road, Jinnan District, Tianjin, 300222, People's Republic of China.
BMC Cardiovasc Disord. 2025 Jul 25;25(1):541. doi: 10.1186/s12872-025-04939-7.
Cardiovascular diseases, particularly atherosclerosis, remain a leading cause of global mortality, presenting significant challenges with non-ST-segment elevation myocardial infarction (NSTEMI). Novel biomarkers such as cluster of differentiation 47 (CD47) and adenylate cyclase-associated protein 1(CAP1) have emerged as potential candidates for improving early diagnosis and risk stratification in NSTEMI patients.
This prospective cohort study was conducted at Tianjin Chest Hospital from November 2023 to June 2024, involving a total of 270 patients categorized into NSTEMI and unstable angina (UA) groups. We used multivariable logistic regression analysis to elucidate the relationship between CD47, CAP1, and the onset of NSTEMI. Receiver operating characteristic (ROC) curve analysis was used to evaluate the diagnostic value of CD47 and CAP1 as biomarkers for the early diagnosis of NSTEMI in the population.Subsequently, Cox regression models were utilized to conduct short-term (median follow-up of 146 days) assessments of patients, evaluating the role of CD47 and CAP1 in early risk stratification.
In our study, CD47 and CAP1 exhibited strong correlations with NSTEMI patients. Furthermore, in ROC analysis, CAP1 (AUC = 0.827, 95% CI: 0.778-0.875, P<0.001) and CD47 (AUC = 0.807, 95% CI: 0.756-0.859, P<0.001) demonstrated robust diagnostic value. Cox regression analysis identified CD47 (HR, 1.059; 95% CI 1.010-1.110; P = 0.018) and CAP1(HR, 5.385; 95% CI 1.769-16.388; P = 0.003) as independent predictors of short-term major adverse cardiovascular events (MACE) in NSTEMI patients. After adjusting some variables, high CD47 group (HR: 4.017, 95%CI 1.320-12.224, P = 0.014) and high CAP1 group (HR: 3.893, 95% CI 1.366-11.090, P = 0.011) the risk of developing MACE was significantly increased in the lower group.
CD47 and CAP1 demonstrated robust diagnostic value for early NSTEMI and great predictive power for short-term MACE in NSTEMI patients.
心血管疾病，尤其是动脉粥样硬化，仍然是全球死亡的主要原因，给非ST段抬高型心肌梗死（NSTEMI）带来了重大挑战。新型生物标志物，如分化簇47（CD47）和腺苷酸环化酶相关蛋白1（CAP1），已成为改善NSTEMI患者早期诊断和风险分层的潜在候选物。
本前瞻性队列研究于2023年11月至2024年6月在天津市胸科医院进行，共纳入270例患者，分为NSTEMI组和不稳定型心绞痛（UA）组。我们使用多变量逻辑回归分析来阐明CD47、CAP1与NSTEMI发病之间的关系。采用受试者工作特征（ROC）曲线分析来评估CD47和CAP1作为生物标志物在人群中早期诊断NSTEMI的诊断价值。随后，利用Cox回归模型对患者进行短期（中位随访146天）评估，评估CD47和CAP1在早期风险分层中的作用。
在我们的研究中，CD47和CAP1与NSTEMI患者表现出强烈的相关性。此外，在ROC分析中，CAP1（AUC = 0.827，95%CI：0.778 - 0.875，P < 0.001）和CD47（AUC = 0.807，95%CI：0.756 - 0.859，P < 0.001）显示出强大的诊断价值。Cox回归分析确定CD47（HR，1.059；95%CI 1.010 - 1.110；P = 0.018）和CAP1（HR，5.385；
